Abstract

The method of generating multipotent stem cells is a method for producing and/or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1−/− murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

IPC Classes  ?

• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 15/86 - Viral vectors

Abstract

Disclosed are systems, methods, and other implementations, including a method for monitoring and managing battery performance that includes deriving a representation of diffusion overpotential behavior for a lithium-ion battery according to a discrete-time state-space approximation of a convolution-defined diffusion (CDD) model for the lithium-ion battery, and determining behavior of the lithium-ion battery according to the discrete-time state-space approximation of the convolution-defined diffusion (CDD) model for the lithium-ion battery.

IPC Classes  ?

• G01R 31/388 - Determining ampere-hour charge capacity or SoC involving voltage measurements
• G01R 31/36 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]
• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells

Abstract

Disclosed are systems, methods, and other implementations, including a method for managing battery performance that includes measuring voltage response data for a lithium-ion battery in response to a current pulse perturbation injected into the lithium-ion battery, and determining in real-time, based on the measured voltage response data, resultant degradation data representative of estimated physical degradation of the lithium-ion battery.

IPC Classes  ?

• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/3835 - Arrangements for monitoring battery or accumulator variables, e.g. SoC involving only voltage measurements

Abstract

A dual function material is provided that captures carbon dioxide from ambient air, i.e., direct air capture, and converts the CO2 to a desired product such as methane. The material includes a high surface area carrier such as Al2O3 upon which catalysts and alkaline adsorbents are positioned proximate each other. In the presence of reactive gas such as hydrogen, the catalysts reduce the adjacent adsorbents to generate additional active sites and enhance the amount of CO2 captured by the material. Once the material becomes saturated with CO2, hydrogen is reintroduced to reduce the catalyst, such as ruthenium, at which time the adsorbed CO2 can migrate from the adsorbent to the catalyst for catalytic conversion to methane. The materials can be employed in isothermal, cyclic reactor systems where target species are bound and then desorbed to reactivate the material, e.g., bind more target species for desorption and/or conversion to additional product.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01J 20/04 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 37/08 - Heat treatment
• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen

Abstract

Method for unified networking for a device in heterogeneous mobile environments includes maintaining and monitoring active network interfaces, managing the location of the device, managing network access security, enabling disruption tolerance support for applications, enabling service sharing and session mobility, managing system parameters for one or more active application sessions, managing storage functionality in one or more memory devices, and maintaining a mapping for one or more flows corresponding to the one or more active application sessions, maintaining one or more policies, and performing flow control decisions based upon the policies using a policy engine. The method can also include monitoring for network events, evaluating whether to perform a handover based upon policies, and providing seamless secure handovers in a heterogeneous mobile environment. A device, non-transitory computer-readable medium, and a system for unified networking are also provided.

IPC Classes  ?

• H04W 76/16 - Setup of multiple wireless link connections involving different core network technologies, e.g. a packet-switched [PS] bearer in combination with a circuit-switched [CS] bearer
• H04L 43/08 - Monitoring or testing based on specific metrics, e.g. QoS, energy consumption or environmental parameters
• H04L 47/193 - Flow control; Congestion control at layers above the network layer at the transport layer, e.g. TCP related
• H04L 47/20 - Traffic policing
• H04L 61/103 - Mapping addresses of different types across network layers, e.g. resolution of network layer into physical layer addresses or address resolution protocol [ARP]
• H04L 61/4511 - Network directories; Name-to-address mapping using standardised directory access protocols using domain name system [DNS]
• H04L 61/5084 - Providing for device mobility
• H04L 69/321 - Interlayer communication protocols or service data unit [SDU] definitions; Interfaces between layers
• H04W 28/02 - Traffic management, e.g. flow control or congestion control
• H04W 36/00 - Handoff or reselecting arrangements
• H04W 36/16 - Performing reselection for specific purposes

Abstract

Disclosed herein are methods of diagnosing a disease or condition associated with abnormal platelet activation in a subject. Also disclosed herein are methods for assessing the propensity of donor platelets to release an uptaken fluorescent false neurotransmitter (FFN).

IPC Classes  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• C07D 221/08 - Aza-anthracenes
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Exemplary embodiments of the present disclosure provides biomaterials, systems, and methods that utilize upconversion biomaterials to stimulate optogenetic cells in three-dimensional settings. Provided is a biomaterial including chromophores capable of converting low-energy light to high-energy light embedded in biocompatible materials. This technology enables more selective stimulation of optogenetic cells in three-dimensional scaffolds and has the potential to provide critical insights into cell function and disease.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

Described herein is a therapeutic method that specifically addresses tumor-infiltrated regulatory T cells (Tregs) with minimal impact on the peripheral Tregs.

IPC Classes  ?

• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to delta-2-tubulin and its use as a biomarker for determining if a subject is at risk of developing peripheral neuropathy or if a subject has developed peripheral neuropathy. The present disclosure further relates to methods for the treatment of peripheral neuropathy in a subject and assays for identifying compounds that can be used to treat and/or prevent peripheral neuropathy.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/69 - Boron compounds
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention provides a compound having the structure: The present invention provides a compound having the structure: wherein R1 is —(C2-C12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R2 is H, halogen, —NO2, —CN, —CF3, —CF2H, —CH2OCH3, —CF2CH3, —CF2OCH3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), —OH, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(haloalkyl), —O-(aryl), —O-(heteroaryl), —OCF3, SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —N-(alkyl)2, NH-(aryl), —NH-(heteroaryl), —CO2H, —CO2-(alkyl), —C(O)—NH2, —C(O)—NH-(alkyl), —C(O)—NH-(aryl), —SO2CH3 or —Si(CH3) 3; R3 is —OCH3, —OCH2CH3, —F or —Cl; and R4 is —OCH3, —OCH2CH3 or —SCH3; wherein when R1 is —CH2CH3, R3 is —OCH3, and R4 is —OCH3, then R2 is other than H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH2OH, —CH(OH) CH3, —OH, —OCH2CH3, —OCH2CH2CH3, —OCH(CH3)2, —SCH3, —SCH2CH3, —SCH2CH2CH3, —NO2, —NH2, —F, —Cl, —Br or —I, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
• C07C 255/59 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
• C07C 317/32 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 323/32 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
• C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

The present disclosure relates to the methods and systems for multimodal profiling. The method can include stabilizing a target, performing a tagmentation on the target using an agent, and generating a library using a reverse transcriptase enzyme. The agent can include a Tn5 transposome complex, a Tn5 transposase reagent, or a combination thereof, and the Tn5 transposome complex or the Tn5 transposase reagent can be loaded with an adapter. The reverse transcriptase enzyme can be configured to transcribe DNA from both a DNA template and an RNA template and perform a terminal transferase activity by template switching and an introduction of an adapter sequence into a cDNA and a transposed chromatin of the target.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present disclosure provides, inter alia, chimeric nanobody compositions that selectively modulate the function of a target protein within a defined population of cells. Also provided are methods for treating diseases such as ion channelopathies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The present disclosure provides, inter alia, compositions and methods for treating or ameliorating the effect of a disorder such as, e.g., anxiety or depression in a subject, with less or no off- and/or on-target side effects. Also provided are methods for treating such disorder in a pregnant woman.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/51 - Nanocapsules
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Systems and methods for generating one or more single crystal monolayers from two-dimensional van der Waals crystals are disclosed herein. Example methods include providing a bulk material including a plurality of van der Waals crystal layers, and exfoliating one or more single crystal monolayers of van der Waals crystal from the bulk material by applying a flexible and flat metal tape to a surface of the bulk material. In certain embodiments, the one or more single crystal monolayers can be assembled into an artificial lattice. The present disclosure also provides techniques for manufacturing flexible and flat metal tape for generating one or more single crystal monolayers from two-dimensional van der Waals crystals. The present disclosure also provides compositions for creating a macroscopic artificial lattice. In certain embodiments, the composition can include two or more macroscopic single crystal monolayers adapted from a bulk van der Waals crystal, where the single crystal monolayers are configured for assembly into an artificial lattice based on one or more properties.

IPC Classes  ?

• C30B 33/00 - After-treatment of single crystals or homogeneous polycrystalline material with defined structure
• B32B 7/02 - Physical, chemical or physicochemical properties
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• B32B 37/00 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
• B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
• B32B 43/00 - Operations specially adapted for layered products and not otherwise provided for, e.g. repairing; Apparatus therefor
• C23C 14/16 - Metallic material, boron or silicon on metallic substrates or on substrates of boron or silicon
• C23C 14/30 - Vacuum evaporation by wave energy or particle radiation by electron bombardment
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 29/68 - Crystals with laminate structure, e.g. "superlattices"

Abstract

A structured material is provided that includes a substrate and a porous structured polymer layer disposed thereon. The porous structured polymer layer includes a plurality of voids, and has a high hemispherical reflectance a high a hemispherical thermal emittance. The structured material is thus particularly advantageous for cool-roof coatings, enabling surfaces coated by the material to stay cool, even under strong sunlight. The material can be produced via structuring of polymers in a mixture including a solvent and a non-solvent. Sequential evaporation of the solvent and the non-solvent provide a polymer layer with the plurality of voids.

IPC Classes  ?

• G02B 26/00 - Optical devices or arrangements for the control of light using movable or deformable optical elements
• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• C08K 5/00 - Use of organic ingredients
• C09D 5/33 - Radiation-reflecting paints
• E04D 7/00 - Roof covering by sealing masses applied in situ; Gravelling of flat roofs
• E04D 13/00 - Special arrangements or devices in connection with roof coverings; Roof drainage
• E04F 13/08 - Coverings or linings, e.g. for walls or ceilings composed of covering or lining elements; Sub-structures therefor; Fastening means therefor composed of a plurality of similar covering or lining elements
• E06B 9/24 - Screens or other constructions affording protection against light, especially against sunshine; Similar screens for privacy or appearance
• G02B 1/14 - Protective coatings, e.g. hard coatings
• G02B 5/20 - Filters

Abstract

A process, apparatus, and cyclopropenimine (CPI) material for generating metal carbonates are disclosed. Generating the metal carbonates comprises reacting carbon dioxide (CO2) with CPI. Generating the metal carbonates also comprises forming a reaction mixture comprising water, metal cations, and a product of the reacting.

IPC Classes  ?

• C07C 251/18 - Compounds containing nitrogen atoms doubly- bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of rings other than six-membered aromatic rings
• C01D 7/14 - Preparation of sesquicarbonates
• C01F 5/24 - Magnesium carbonates
• C01F 11/18 - Carbonates

Abstract

This application describes Swept, Confocally-Aligned Planar Excitation (SCAPE) microscopy systems that incorporate a gradient index (GRIN) lens to relay images from their distal tip to their proximal tip so that 3D images of deep tissue can be captured, without undue loss of light. A zero working distance feature can be designed into the third objective to ensure that the light that exits the second objective in the SCAPE system is not lost. Alternatively, a tapered fiber bundle may be positioned between the second objective and the third objective in the SCAPE system to ensure that the light that exits the second objective is not lost. As yet another alternative, direct detection at the intermediate image plane without using a third objective can ensure that the light that exits the second objective in the SCAPE system is not lost.

IPC Classes  ?

• G02B 21/00 - Microscopes
• G02B 3/00 - Simple or compound lenses
• G02B 21/33 - Immersion oils
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes

Abstract

Anti-Fn amyloid-like FadA antibodies and compositions are provided and methods of treating cancers, including pancreatic and colorectal, and periodontal diseases. Methods include preventing, reducing development, or treating disease in a subject in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which inhibits or blocks an amyloid-like FadA secreted from Fusobacterium nucleatum (Fn).

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

A process, composition, and apparatus for carbon dioxide (CO2) conversion are disclosed. The CO2 conversion comprises reacting CO2 with a cyclopropenimine (CPI) to activate the CO2 and transferring the activated CO2 to generate a product of the transferring. The transferring also generates a conjugate acid of the CPI. The process further comprises regenerating the CPI from the conjugate acid.

IPC Classes  ?

• B01J 20/26 - Synthetic macromolecular compounds
• B01D 53/62 - Carbon oxides
• B01D 53/78 - Liquid phase processes with gas-liquid contact
• B01D 53/96 - Regeneration, reactivation or recycling of reactants
• B01J 20/34 - Regenerating or reactivating

Abstract

Disclosed herein are methods for regulating an immune response using selective activation of neurons in the caudal nucleus of the solitary tract.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo

Abstract

A process, apparatus, and material for generating polymers are disclosed. Generating the polymers comprises reacting carbon dioxide (CO2) with a cyclopropenimine (CPI). Generating the polymers further comprises reacting monomers with a product of the reaction between the CPI and the CO2.

IPC Classes  ?

• C08G 64/32 - General preparatory processes using carbon dioxide
• C08G 64/16 - Aliphatic-aromatic or araliphatic polycarbonates
• C08G 71/04 - Polyurethanes

Abstract

The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Circuit for wake-up receivers are provide. In some embodiments, the wake-up receivers include self-mixers that receive a gate bias voltage. Some of the self-mixers are single ended and some are differential. In some embodiments, the wake-up receivers include a matching network that is connected to the input of the self-mixer. In some embodiments, the wake-up receivers include a low frequency path connected to the output of the self-mixer. In some embodiments, the wake-up receivers include a high frequency path connected to the output of the self-mixer. In some embodiments, the wake-up receivers are configured to receive an encoded bit stream. In some embodiments, the wake-up receivers are configured to wake-up another receiver.

IPC Classes  ?

• H04L 27/06 - Demodulator circuits; Receiver circuits
• H03K 19/0185 - Coupling arrangements; Interface arrangements using field-effect transistors only
• H03K 19/17788 - Structural details for adapting physical parameters for input/output [I/O] voltages
• H04L 27/26 - Systems using multi-frequency codes

Abstract

Rehabilitation or ambulation assistance can be provided to a user by sensing at least one first pressure beneath the user's right foot, sensing at least one second pressure beneath the user's left foot, and predicting the user's gait based on the sensed at least one first pressure and the sensed at least one second pressure. A plurality of motors are energized at a plurality of times that are synchronized with phases of the user's gait so that the plurality of motors pull on respective cables at respective times in a coordinated sequence. Each of the cables has a first end affixed to a pelvic belt or harness that is shaped and dimensioned to fit securely on the user's pelvis, and the timing of the energizing is based on the gait predictions.

IPC Classes  ?

• A61H 3/04 - Wheeled walking aids for patients or disabled persons
• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

A copper concentrate such as chalcopyrite is contacted with an aqueous solution includes acids and a reducing agent, such as vanadium (II) ions, chromium (II) ions, or tungstozincic acid (H6ZnW12O40). The aqueous solution reduces the copper in the copper concentrate, which can then dissolve into the solution for recovery therefrom, or precipitate out of solution as copper compounds or elemental copper for recovery in as a solid phase product. The solid phase product can then be isolated, dissolved, and further electrowinned to recover a copper product from the copper concentrate. Oxidized reducing agent can be recovered in an electrochemical device with ferrous iron reactants. Hydrometallurgical routes to convert copper concentrates to copper are potentially less expensive and less polluting than current pyrometallurgical processing and an advantageous response to environmental and economic pressures for increased copper production.

IPC Classes  ?

• C25C 1/12 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper

Abstract

The subject matter disclosed herein relates to a method of treating glioblastoma (GBM) in a subject in need thereof, the method comprising determining one or more GBM subtypes in a GBM sample via a pathway-based classifier approach and administering to the subject a pharmaceutically effective amount of an agent capable of modifying the activity of the biological pathways associated with the one or more GMB subtypes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

In various aspects and embodiments of the disclosure, the invention provides pharmaceutical compositions and methods for protecting against brain injury associated with Hypoxic-Ischemic Encephalopathy (HIE). The compositions and methods employ omega-3 fatty acid (n-3 FA) diglyceride (DG) and/or triglyceride (TG) emulsions, which may be used alone or in combination with therapeutic Hypothermia (HT).

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/107 - Emulsions
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

A method of detecting or diagnosing squamous cancers in a sample from a subject, including isolating extracellular vesicles from the sample, wherein the extracellular vesicles are cancer specific.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 1/40 - Concentrating samples

Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to methods for regulating cholesterol efflux in retinal pigment epithelium cells and treating or preventing a neurodegenerative disease or disorder (e.g., macular degeneration).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/86 - Viral vectors
• A61K 38/18 - Growth factors; Growth regulators

Abstract

Methods for conversion of a broad range of amines to their 15N isotopic counterparts and the compounds produced thereby.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

Devices and methods for joining a first and second tissue in a patient are disclosed that include a base with a plurality of recurved tines oriented to a tine axis and extending from a first surface of the base. The tines provide unidirectional traction of the first tissue along the tine axis toward the first surface. The first tissue is secured to the first surface of the device at the plurality of recurved tines and the second tissue is secured to the device at a second surface opposite the first surface to join the first and second tissues.

IPC Classes  ?

• A61F 2/08 - Muscles; Tendons; Ligaments
• A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

The present invention relates to methods and compositions for using plasma Indian hedgehog (IHH) as a biomarker for diagnosing, and as a therapeutic target for treating, liver conditions including non-alcoholic steatohepatitis (NASH).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure provides for systems and methods for modifying the epigenome of cells.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 5/0793 - Neurons
• A61K 35/30 - Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A quantitative gait training and/or analysis system employs instrumented footwear and an independent processing module. The instrumented footwear may have sensors that permit the extraction of gait kinematics in real time and provide feedback from it. Embodiments employing calibration-based estimation of kinematic gait parameters are described. An artificial neural network identifies gait stance phases in real-time.

IPC Classes  ?

• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen, e.g., CD33 or EMR2, and a population of hematopoietic cells that are altered in the expression of the lineage-specific cell-surface antigen, e.g., CD33 or EMR2, for immunotherapy of hematological malignancies. Also disclosed herein are methods of administering an agent targeting more than one lineage-specific cell-surface antigen, and a population of hematopoietic cells that are altered in the expression of more than one lineage-specific cell-surface antigen, for immunotherapy of hematological malignancies. Cells comprising mutations in CD33, or EMR2, or more than one lineage-specific cell-surface antigen are also provided, as are methods of producing such cells using CRISPR-based base editor systems.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells
• C12N 9/22 - Ribonucleases

Abstract

Provided herein are methods and compositions related to the use of human monocyte-derived microglia-like (MDMi) cells. In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to assess the effect of a clinical intervention on a human subject (e.g., a subject with a neurodegenerative disorder). In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to stratify human subjects into subgroup populations (e.g., populations that are likely to respond to a clinical intervention or are unlikely to respond to a clinical intervention). In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to identify candidate neurodegenerative disease biomarkers. In certain embodiments, the methods and compositions provided herein relate to the use of MDMi cells to screen potential therapeutic agents to identify candidate agents for the treatment of a neurodegenerative disease.

IPC Classes  ?

• C12N 5/079 - Neural cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

Exemplary method and configuration for a frequency conversion can be provided. For example, such method and configuration can use at least one transition metal dichalcogenide (TDM) crystal (which can include one or more MoS2 crystals, which can be stacked). For example, it is possible to providing at least one radiation to the at least one TDM crystal so as to generate a resultant radiation. Resultant information can be generated by measuring difference frequency and a second harmonic generation (SHG) from the resultant radiation provided from the TDM crystal. The frequency conversion can be obtained or achieved by providing a measurement of a SHG coherence length based on the resultant information.

IPC Classes  ?

• G02F 1/355 - Non-linear optics characterised by the materials used
• G02F 1/35 - Non-linear optics

Abstract

Mechanisms for defending a computing system from attack are provided. The mechanisms include: maintaining a round counter that tracks a round number for a local host; determining a location in a graph for each of a plurality of hosts including the local host; determining monitor hosts of the plurality of hosts that are monitoring the local host; determining monitoree hosts of the plurality of hosts that are being monitored by the local host; sending a message to each of the monitor hosts identifying a value of the round counter; forwarding a first set of heartbeat messages from previous monitoree hosts to the monitor hosts; attempting to receive messages from the monitoree hosts; determining whether any messages were not received from the monitoree hosts; and in response to determining that one or more messages were not received from the monitoree hosts, generating an alert.

IPC Classes  ?

• H04L 9/40 - Network security protocols
• G06F 7/58 - Random or pseudo-random number generators
• G06F 9/54 - Interprogram communication
• G06F 21/60 - Protecting data
• G06F 21/54 - Monitoring users, programs or devices to maintain the integrity of platforms, e.g. of processors, firmware or operating systems during program execution, e.g. stack integrity, buffer overflow or preventing unwanted data erasure by adding security routines or objects to programs

Abstract

A method of treating a condition in a subject by improving the immune response of the subject comprising first determining the level of TCF1 in the subject to identify the subject as having an anti-PD-1 responder phenotype or an anti-PD-1 non-responder phenotype, then administering an anti-PD-1 treatment to a subject having an anti-PD-1 responder phenotype or a metabolic inhibitor prior to ant-PD-1 treatment to a subject having an anti-PD-1 non-responder phenotype.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/52 - Purines, e.g. adenine
• A61P 37/02 - Immunomodulators

Abstract

A system combining programmable bacteria cells that produce one or more antigens and optionally one or more cytokines and CAR-T cells that recognize and respond to at least one of the antigens to elicit an immune response against tumors and treat hyperproliferative disorders.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 35/74 - Bacteria
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present disclosure provides compositions and methods of treating motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). A modulator of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a mutant heat shock protein may be used.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/761 - Adenovirus
• A61K 38/46 - Hydrolases (3)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The disclosed matter provides systems and methods for encoding an assembly of three-dimensional (3D) hierarchically ordered nanoparticle architectures through chromatic bonds. Through identification of the repeating mesovoxels including chromatic bonds and voxels, the presented disclose matter can allow for encoding the 3D architectures by using symmetries of mesovoxel, enable a compression of the information amount required for encoding.

IPC Classes  ?

• G16B 15/10 - Nucleic acid folding
• G01N 23/201 - Measuring small-angle scattering, e.g. small angle X-ray scattering [SAXS]
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

Disclosed are devices, systems, apparatus, methods, products, and other implementations, including a method comprising obtaining, by a device, a combined sound signal for signals combined from multiple sound sources in an area in which a person is located, and applying, by the device, speech-separation processing (e.g., deep attractor network (DAN) processing, online DAN processing, LSTM-TasNet processing, Conv-TasNet processing), to the combined sound signal from the multiple sound sources to derive a plurality of separated signals that each contains signals corresponding to different groups of the multiple sound sources. The method further includes obtaining, by the device, neural signals for the person, the neural signals being indicative of one or more of the multiple sound sources the person is attentive to, and selecting one of the plurality of separated signals based on the obtained neural signals. The selected signal may then be processed (amplified, attenuated).

IPC Classes  ?

• G10L 25/30 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the analysis technique using neural networks
• G10L 17/26 - Recognition of special voice characteristics, e.g. for use in lie detectors; Recognition of animal voices

Abstract

Devices for radiative cooling and optical waveguiding are provided, wherein the devices comprise a fabric including one or more fibers extending for a length in a longitudinal direction and a plurality of void structures positioned within each of the one or more fibers and extended over the length of each of the one or more fibers. Each of the plurality of void structures is configured to scatter at least a portion of an electromagnetic radiation received thereon to thereby radiatively cool the object.

IPC Classes  ?

• F28F 13/00 - Arrangements for modifying heat transfer, e.g. increasing, decreasing
• D01D 5/06 - Wet spinning methods
• D01D 5/16 - Stretch-spinning methods using rollers, or like mechanical devices, e.g. snubbing pins
• D01D 5/247 - Discontinuous hollow structure or microporous structure
• D01F 1/04 - Pigments
• D01F 2/00 - Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof
• D01F 4/02 - Monocomponent artificial filaments or the like of proteins; Manufacture thereof from fibroin
• D01F 6/12 - Monocomponent man-made filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of halogenated hydrocarbons from polymers of fluorinated hydrocarbons
• G02B 6/10 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• D01D 1/10 - Filtering or de-aerating the spinning solution or melt
• D06M 11/00 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
• D01D 1/06 - Feeding liquid to the spinning head
• D01F 1/06 - Dyes
• D01F 1/10 - Other agents for modifying properties

Abstract

The system includes electrolyzers to generate acidic and alkaline effluent streams from saltwater. The electrolyzer include stacked pairs of porous anodes and cathodes that define feed channels into which reactants, e.g., hydrogen and brine, can be pumped to undergo an oxidation-reduction reaction. The porous cathode carries out the HER to generate H2, which floats upwards to the porous anode, where it is oxidized through the HOR. The reaction can thus progress in a self-maintaining manner. The HER creates an alkaline product stream with increased basicity, and the HOR an acidic product stream with increased acidity, compared to the inlet stream. Streams are pumped through the porous electrodes and the electrolyzer to sweep effluent through separate channels before they can combine. The alkaline product stream can have an alkalinity sufficient to drive metal ion precipitation in raw saltwater prior to feeding to the electrolyzer to reduce fouling/degradation of electrolyzer electrodes.

IPC Classes  ?

• C25B 9/70 - Assemblies comprising two or more cells
• C25B 11/031 - Porous electrodes
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 1/26 - Chlorine; Compounds thereof
• C25B 15/08 - Supplying or removing reactants or electrolytes; Regeneration of electrolytes

Abstract

Anti-annexin A1 antibodies are provided and methods of treating FAP and cancer using Anti-annexin A1 antibodies, antibody fragments or fusion proteins, including bispecific antibodies targeting two different annexin A1 epitopes, are also provided.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed herein is a kit for detecting or quantifying a SARS-CoV-2 nucleocapsid phosphoprotein, including a first antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 12, 14, 16, 18, 20, and 22; and a second antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 9 and 13, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 14.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present disclosure relates to methods and compositions for increasing or extending lifespan and/or healthspan and/or delaying aging using agents which mimic the effects of time-restricted feeding and/or activate or enhance circadian-regulated autophagy. In particular, the present disclosure relates to increasing certain proteins including UNC-51-like kinase (ULK1), adenosine monophosphate protein kinase (AMPK) and microtubule-associated protein, light chain 3 (LC3), and decreasing other certain proteins including ribosomal protein S6 kinase beta-1 (S6K) protein in order to increase lifespan and/or healthspan and delay aging.

IPC Classes  ?

• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/18 - Sulfonamides
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Abstract

The invention described relates to the newly discovered ability of tumor internalizing arginylglycylaspartic acid (iRGD) peptides to alter the immune cell landscape in pancreatic ductal adenocarcinoma (PDAC) and other cancers. The iRGD peptides sensitize the cancer to immune checkpoint inhibitors, for example anti-PD-L1, anti-PD-L1, anti-PD-1, and anti-CTLA4 monoclonal antibodies to specifically deplete Tregs within the tumor, resulting in expansion of intratumoral CD8+ T cells (effector cells). This provides methods of treating cancers such as PDAC, preferably in synergistic combination with chemotherapy and immunotherapy, which leads to reduced tumor burden and prolonged survival.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

An energy storage system comprises a plurality of electrochemical cells. The electrochemical cells include a pair of electrodes including an anode and a cathode. An electrolyte in communication with the pair of electrodes. A flow shaping baffle is situated between the pair of electrodes. The flow shaping baffle includes a plurality of channels extending from a first end proximate the cathode to a second end proximate the anode along an axis substantially perpendicular to the electrodes. The first end has a first diameter and the second end has a second diameter. The first diameter is greater than the second diameter. The disclosed energy storage system does not require expensive pumps or ion exchange membranes and can operate efficiently over a long service life.

IPC Classes  ?

• H01M 10/36 - Accumulators not provided for in groups
• H01M 12/08 - Hybrid cells; Manufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/0258 - Collectors; Separators, e.g. bipolar separators; Interconnectors characterised by the configuration of channels, e.g. by the flow field of the reactant or coolant

Abstract

A quantitative gait training and/or analysis system includes one or more footwear modules that may include a piezoresistive sensor, an inertial sensor and an independent logic unit. The footwear module functions to permit the extraction of gait kinematics and evaluation thereof in real time, or data may be stored for later reduction and analysis. Embodiments relating to calibration-based estimation of kinematic gait parameters are described, as well as biofeedback embodiments useful in training runners to maintain a time-varying target velocity or pace.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

This invention provides methods for detecting viruses, viral antigens, viral antibodies, and other antigens and antibodies using single molecule electronic nanopores and polymer tags.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/537 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody

Abstract

In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

Abstract

The disclosure provides FOXO1 inhibitors having beneficial properties such as selectivity and metabolic stability. FOXO1 inhibitors are useful in the treatment of diabetes.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Disclosed herein are methods for detecting methylation in cell-free polynucleotides and methods for detecting the presence of cancer in a subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure provides for a pharmaceutical composition comprising ubiquinone-5 (UB5) and method of use thereof. The present disclosure relates to ubiquinone-5 used as an anesthetic, sedative agent, hypnotic agent, or combination thereof.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/107 - Emulsions
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 23/00 - Anaesthetics

Abstract

Disclosed are methods, systems, devices, and other implementations, including a voltage converter system that includes a plurality of energy storage elements, a plurality of switching devices, each of which is in electrical communication with at least one of the plurality of the storage elements, with the plurality of storage elements and the plurality of switching devices being configured in a multi-level arrangement of multiple voltage converting cells. The system further includes a plurality of controllers to actuate one or more of the plurality of switching devices to independently control voltage levels of at least one energy storage element of the multiple voltage converting cells. In some embodiments, the cells may include an arrangement of two capacitors and an inductor that define a buck-boost converter circuit. Alternatively, the cells may have a Dual Active Half Bridge (DAHB) converter configuration with a primary side separated from a secondary side by a transformer.

IPC Classes  ?

• H02M 3/335 - Conversion of dc power input into dc power output with intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate ac using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
• H02M 3/158 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load
• H02M 7/483 - Converters with outputs that each can have more than two voltage levels
• H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
• H02P 27/14 - Arrangements or methods for the control of AC motors characterised by the kind of supply voltage using variable-frequency supply voltage, e.g. inverter or converter supply voltage using dc to ac converters or inverters with pulse width modulation with three or more levels of voltage

Abstract

A spacer for an immersion objective lens can be fabricated by pressing a set of sidewalls onto a mirror to form a liquid-tight cavity, filling the liquid-tight cavity with a first quantity of a UV-curable polymer, and curing the first quantity of the UV-curable polymer into a first solid mass that will be adhered to the mirror. The upper surface of the first solid mass is then positioned near the objective lens, with a second quantity of a UV curable polymer occupying the space between the first solid mass and the objective lens. Next, the position of the first solid mass is adjusted until it reaches a final position with respect to the objective lens. This adjustment may be assisted by checking the collimation of light reflected back through the mirror. The second quantity of the UV curable polymer is then cured.

IPC Classes  ?

• G02B 21/00 - Microscopes
• G02B 21/02 - Objectives

Abstract

The present subject matter relates to techniques for treating a neurodegenerative disease. The disclosed system can include a transducer for stimulating a target tissue with focused ultrasound (FUS) and at least one nanocup. The transducer induces the FUS with a predetermined parameter to open the target tissue. The nanocup can include at least one gas pocket within a cavity of the nanocup and an effective amount of an active agent for neuroregeneration.

IPC Classes  ?

• A61N 7/00 - Ultrasound therapy

Abstract

Disclosed herein are engineered heterodimer or heterotrimer proteins which use a non-naturally occurring polypeptide domain comprising 1-5 alpha helices connected by amino acid linkers and an IgG2 hinge domain either alone or in conjunction with an IgG2 Fc domain. The heterodimer and heterodimer proteins can further comprise an antigen-binding fragment that binds a lineage-specific cell-surface antigen, a polypeptide that binds to a molecule expressed on an immune cell (e.g., natural killer cell) and/or a polypeptide that binds to a molecule expressed on another type of immune cell (e.g., T cells). Also disclosed herein are nucleic acids encoding the proteins, vectors comprising the nucleic acids, compositions, and methods of treatment.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/74 - Major histocompatibility complex (MHC)
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present disclosure provides vectors comprising a transgene(s) encoding more than one isoform of Crumbs homologue-1 (CRB1) (e.g., CRB1-A and CRB1-B), and compositions thereof, for use in the treatment or prevention of CRB1-related diseases and disorder (e.g., autosomal recessive retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA)).

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 27/02 - Ophthalmic agents
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

Abstract

The present disclosure relates to methods and compositions for elevating and stabilizing retromer protein for treating and/or preventing neurodegenerative diseases and disorders including Alzheimer's disease and Parkinson's disease, where retromer dysfunction and/or endosomal trafficking dysfunction is involved and/or implicated in the disease or disorder. The methods include the use of agents to elevate and stabilize specific retromer depending upon the neurodegenerative disease or disorder being treated. The method can also include the use of one or more biomarkers to detect and/or identify whether retromer dysfunction and/or endosomal trafficking dysfunction is involved and/or implicated in the disease or disorder.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C12N 15/86 - Viral vectors
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Systems, methods, devices, and apparatuses generate a fully integrated broadband high power frequency combs, based on a multimode gain chip. Embodiments can generate a frequency comb spanning over ˜150 nm and include self-injection locking of a multimode chip-based gain, which can allow access to high pump power while maintaining single mode operation. The integrated frequency comb systems and methods can comprise a multimode gain chip, a ring resonator in optical communication with a waveguide and, and an integrated heater in thermal communication with the ring resonator. Embodiments can be configured to receive multimode gain input and effect a single-mode ring feedback to determine a target mode. A temperature of the ring resonator can be optionally adjusted to modulate the ring feedback, and the ring feedback can be applied to the multimode gain input to generate an output frequency comb that includes the target mode.

IPC Classes  ?

• G02F 1/35 - Non-linear optics
• G02F 1/39 - Non-linear optics for parametric generation or amplification of light, infrared, or ultraviolet waves

Abstract

A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to one or more neurological conditions.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

A photocatalyst suspension reactor for solar fuel formation. The reactor may comprise a shallow pool filled with a first portion of an electrolyte solution. The electrolyte solution may comprise a solvent, a plurality of redox shuttle molecules, and a plurality of photocatalyst particles. The reactor may further comprise a plurality of tubes disposed on a surface of the shallow pool, each tube of the plurality of tubes comprising an upper half and a lower half. The upper half may comprise a transparent material configured to be minimally permeable to hydrogen gas and oxygen gas. The lower half may be configured to be filled with a second portion of the electrolyte solution and comprises an ion bridge material permeable to the plurality of redox shuttle molecules and minimally permeable to the plurality of photocatalyst particles.

IPC Classes  ?

• B01J 8/08 - Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with moving particles
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
• C01B 3/50 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification

Abstract

The present disclosure relates to methods and compositions useful for the identification of a ryanodine receptor modulator binding site in ryanodine receptor type 1 (RyR1). The present disclosure also provides compositions useful for the analysis of the ryanodine receptor modulator binding site in RyR1 via cryoEM. The present disclosure further provides computational methods for identifying compounds that bind to RyR1.

IPC Classes  ?

• G16C 20/50 - Molecular design, e.g. of drugs
• G16C 20/70 - Machine learning, data mining or chemometrics
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]

Abstract

Disclosed are implementations, including a method that includes obtaining measurement samples relating to electrical operation of an electric motor drive providing power to an electric motor, deriving, based on the samples, instantaneous estimates for parameters characterizing speed and/or position of the motor according to an optimization process based on a cost function defined for the samples, and applying a filtering operation to the instantaneous estimates to generate filtered values of the motor's speed and/or position. The filtering operation includes computing the filtered values using the derived instantaneous estimates in response to a determination that a computed convexity of the cost function is greater than or equal to a convexity threshold value, and/or applying a least-squares filtering operation to the derived instantaneous estimates and using at least one set of previous estimates derived according to the optimization process applied to previous measurement samples.

IPC Classes  ?

• H02P 21/13 - Observer control, e.g. using Luenberger observers or Kalman filters
• H02P 21/18 - Estimation of position or speed
• H03H 21/00 - Adaptive networks

Abstract

Disclosed are methods, systems, devices, and other implementations, including a voltage converter device that includes one or more inductive elements to deliver inductor current to an output section of the voltage converter device, at least one switching device to control current flow at the output section of the voltage converter device, and a controller to controllably vary, according to a predictive model, a subsequently applied switching frequency to the at least one switching device to maintain zero-voltage switching based, at least in part, on the inductor current of the one or more inductive elements.

IPC Classes  ?

• H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
• H02M 3/158 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load

Abstract

The present invention provides a compound having the structure: The present invention provides a compound having the structure: wherein D, E and F are each independently NR1, CR2R3 or CR6R7, wherein one of D, E and F is NR1 and the remaining two are CR2R3 or CR6R7, wherein R1 is H or -(alkyl), and wherein R2, R3, R6 and R7 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl; X1 is C or N; X2 is O, S, N, NR14 or CR15, wherein R14 is H, -(alkyl) or -cycloalkyl, wherein R15 is H, -(alkyl) or -cycloalkyl, and wherein X2 is other than N when X1 is N; α and β represent a bond that is present or absent, and wherein either α or β is present, wherein when α is present, then X1 is C and X2 is O, S or NR14, or when β is present, then X1 is N and X2 is N or CR15; R4, R5, R8 and R9 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl, -alkylaryl, —OH, —O(alkyl), —OAc, —S(alkyl), —NH2, —NH(alkyl), —N(alkyl)2, —COOH, —CO2(alkyl), —CONH2, —CONH(alkyl), —CON(alkyl)2 or —CN, wherein when D is NR1 then R4 and R5 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl, wherein when F is NR1 then R8 and R9 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl or R1 and R4 together form a —(CH2)m—, wherein m represents an integer from 2 to 4; and R10, R11, R12 and R13 are each independently H, halogen, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -(aryl), -(heteroaryl), —OH, —OAc, —O(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —SH, —S(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —CO2(alkyl), —CONH2, —CN, —CF3, —CF2H, —OCF3 or NO2 or R10 and R11 together form a —O(CH2)O— or R11 and R12 together form a —O(CH2)O— or R12 and R13 together form a —O(CH2)O—; wherein when X1 is C, X2 is NR14, and D is CR2R3, E is NR1, F is CR6R7, then (i) R14 and at least two of R10, R11, R12 and R13 are other than hydrogen, or (ii) one of R2, R3, R6 and R7 is other than H, wherein when X1 is C, X2 is O, and E is NH, NCH3, NCH2CH3, or NCH(CH3)2, and one of R10, R11, R12 and R13 is —OCH3 or —SCH3, then (i) one of R2, R3, R4, R5, R6, R7, R8 or R9 is other than H, or (ii) at least two of R10, R11, R12 and R13 are other than H, wherein when X1 is C, X2 is O, and F is NH, then at least one of R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 or R13 is other than H, wherein when X1 is C, X2 is S, and R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each H, and R11 is Br, then D and E is other than NH, wherein when X1 is N, X2 is CR15, D is CR2R3, E is NR1, F is CR6R7, and R1, R2, R3, R4, R5, R6, R7, R8 and R9 are H, and R15 is H, then one of R10, R11, R12 or R13 is other than H, and R10 is other than OMe, R11 is other than Br, R12 is other than Br and Cl, and R13 is other than OMe, wherein when X1 is N, X2 is CR15, D is CR2R3, E is NR1, F is CR6R7, R1 is alkyl, R2, R3, R4, R5, R6, R7, R8 and R9 are H, and R15 is CH3, then at least one of R10, R11, R12 or R13 is other than H and CH3, and R11 is other than a ketone and a carboxylic acid, wherein when R1 and R4 together form a —(CH2)3—, X1 is C, X2 is NR14, D is CR2R3, E is NR1, F is CR6R7, and R2, R3, R5, R6, R7, R8, R9, R10, R12, R13 and R14 are each H, then R11 is other than H, F or —CH3, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 487/18 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/18 - Bridged systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 495/04 - Ortho-condensed systems
• C07D 495/18 - Bridged systems

Abstract

Disclosed are methods, systems, device, and other implementations, including a method (performed by, for example, a hearing aid device) that includes obtaining a combined sound signal for signals combined from multiple sound sources in an area in which a person is located, and obtaining neural signals for the person, with the neural signals being indicative of one or more target sound sources, from the multiple sound sources, the person is attentive to. The method further includes determining a separation filter based, at least in part, on the neural signals obtained for the person, and applying the separation filter to a representation of the combined sound signal to derive a resultant separated signal representation associated with sound from the one or more target sound sources the person is attentive to.

IPC Classes  ?

• G10L 21/028 - Voice signal separating using properties of sound source
• G10L 21/0232 - Processing in the frequency domain
• G10L 21/0208 - Noise filtering

Abstract

Disclosed are methods, systems, and other implementations, including a method for identifying and predicting illegal digital currency transactions that includes obtaining one or more blockchains of transaction blocks for transactions involving digital currency, deriving from the one or more blockchains of transaction blocks a transaction graph of sequential transactions, and applying clustering processing to the transaction graph to generate resultant one or more entity graphs representative of likely chains of digital currency transfers by respective one or more entities. The method further includes extracting graph feature data from the resultant one or more entity graphs, and applying classification processing (e.g., supervised learning classification processing) to the extracted graph feature data to identify a suspected malicious entity from the one or more entities associated with the one or more entity graphs.

IPC Classes  ?

• G06F 21/56 - Computer malware detection or handling, e.g. anti-virus arrangements
• G06F 21/55 - Detecting local intrusion or implementing counter-measures
• G06Q 20/02 - Payment architectures, schemes or protocols involving a neutral third party, e.g. certification authority, notary or trusted third party [TTP]

Abstract

Mechanisms including: receiving a first set of observed spike counts (FSoOSCs) for the spiking cells; determining a set of probabilities (SoPs) by: retrieving the SoPs from stored information (SI); or calculating the SopS based on the SI, wherein the SI regards possible biological states (BSs) of a subject, wherein each of the possible BSs belongs to at least one of a plurality of time sequences (PoTSs) of BSs, wherein each of the PoTSs of BSs corresponds to a possible action of the subject, and wherein each probability in the set of probabilities indicates a likelihood of observing a possible spike count for one of the plurality of spiking cells; identifying using a hardware processor a first identified BS of the subject from the possible BSs based on the FSoOSCs and the set of probabilities; and determining an action to be performed based on the first identified BS.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

The present invention relates to monolayer cardiac differentiation techniques utilizing defined conditions providing feeder-free monolayer culture systems, serum-based or serum free, and applicable to both healthy control and patient derived stem cells.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/074 - Adult stem cells

Abstract

An enhanced delivery vehicle for a treating agent includes a base delivery vehicle, which is adapted for carrying a treating agent for uptake thereof by a target cell, and an enhancing component. The enhancing component may be at least one energy rich substance, at least one agent which increases production of at least one energy rich substance in the target cell, or a combination thereof. The enhancing component enhances the uptake of the base delivery vehicle by the target cell. Non-limiting examples of the base delivery vehicle include exosomes, microvesicles, apoptotic bodies, oncosomes, extracellular vesicles, microparticles, liposomes, and nanoparticles. In one embodiment, the enhancing component is an exosome engineered to be substantially devoid of endogenous nucleic acids. In one embodiment, the enhancing component is at least one energy rich substance including, but not limited to, ATP, NADH, NADPH, FADH2, acetyl CoA, glucose, pyruvate, GTP, CTP, and UTP.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed herein are methods for identifying subjects, diagnosed as having glioblastoma (GBM), as likely responders to treatment with a programmed death protein 1 (PD-1) blockade. In some embodiments, the subjects are identified by determining the level of phosphorylated extracellular-signal-regulated kinase (p-ERK) in a GBM tumor sample from the subject. In some embodiments, the GBM is recurrent. Also disclosed herein are methods of treating GBM subjects, whereby the methods include (1) identifying the subject as a likely responder to PD-1 blockade, and (2) administering a PD-1 inhibitor and/or a programmed death-ligand 1 (PD-L1) inhibitor.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention provides, inter alia, methods for systemically treating or preventing graft-versus-host disease (GVHD) in a subject using a GLP-2 analogue or GLP-2 agonist. Also provided are methods for treating an autoimmune disorder in a subject, methods for improving the effect of a cancer treatment in a subject in need thereof, methods for systemically treating an inflammatory condition in a subject caused by solid organ transplant rejection, and methods for reducing high-dose chemotherapy- and/or radiotherapy-induced GI mucositis, using a GLP-2 analogue or GLP-2 agonist.

IPC Classes  ?

• A61K 38/26 - Glucagons
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The disclosed subject matter provides systems and methods for processing light. An example system can include one or more substrates, and a plurality of meta-units, which are patterned on each of the substrates and configured to modify a phase, an amplitude, or a polarization of the light with a subwavelength resolution. The system can be in a form of a diffractive neural network and be configured to perform target recognition.

IPC Classes  ?

• G06N 3/067 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using optical means
• G02B 5/18 - Diffracting gratings

Abstract

A heart valve replacement is provided including a tubular body portion having a proximal end, a distal end and a central portion arranged between said proximal and distal ends, defining a longitudinal direction of the valve replacement and having an inner wall region; a valve having at least one leaflet attached to the inner wall region of the central portion, each one of said leaflets being movable between a closing position and an opening position of the valve, wherein the tubular body portion is fabricated from a combination of a biostable polymer and a biodegradable biomaterial adapted to allow in-growth of tissue of the host and to increase its size concomitantly with surrounding organ structures of a host, and wherein the valve is fabricated of a biostable polymer connected to the biostable polymer of the tubular body portion.

IPC Classes  ?

• A61F 2/24 - Heart valves
• D01F 6/62 - Monocomponent man-made filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters
• D01F 6/70 - Monocomponent man-made filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyurethanes
• D01D 5/00 - Formation of filaments, threads, or the like
• B33Y 80/00 - Products made by additive manufacturing

Abstract

A composite panel includes a first carbon fiber layer and a first glass fiber layer. A first carbon fiber sensor includes a first plurality of carbon fiber tows. The composite panel includes a second glass fiber layer and a second carbon fiber layer. The first carbon fiber sensor is arranged between the first glass fiber layer and the second glass fiber layer. The first carbon fiber layer and the second carbon fiber layer are arranged adjacent to the first glass fiber layer and the second glass fiber layer, respectively.

IPC Classes  ?

• G01N 27/20 - Investigating the presence of flaws
• B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
• B32B 3/08 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by features of form at particular places, e.g. in edge regions characterised by added members at particular parts

Abstract

The present disclosure relates to methods and compositions useful for the identification of a ryanodine receptor modulator binding site in ryanodine receptor type 2 (RyR2). The present disclosure also provides compositions useful for the analysis of the ryanodine receptor modulator binding site in RyR2 via cryo-EM. The present disclosure further provides computational methods for identifying compounds that bind to RyR2.

IPC Classes  ?

• G16B 15/30 - Drug targeting using structural data; Docking or binding prediction
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present subject matter relates to techniques for electromechanical wave imaging. The disclosed system can include a processor that can be configured to perform an automated selection of at least one zero-crossing location using a heuristic-based baseline and/or a machine learning classifier and generate an electromechanical wave imaging isochrone based on the automated selection.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings

Abstract

The subject method described herein relates to a method of treating, preventing, or reducing the incidence of Acute Kidney Injury (AKI) in a subject in need thereof by administering to the subject a pharmaceutically effective amount of one or more amino acids.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The disclosed matter provides integrated metasurface devices for conversion between a waveguide mode and a free-space optical wave with a designer wavefront. In exemplary embodiments, the integrated metasurface devices include a thin waveguide, a waveguide taper, a leaky-wave metasurface defined within a high refractive index layer of dielectric material, and a low refractive index substrate. The device can manipulate all the four optical degrees of freedom of the free-space wavefront, namely: amplitude, phase, polarization orientation, and polarization ellipticity, by using a leaky-wave metasurface composed of meta-units with four structural degrees of freedom.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
• G02B 6/122 - Basic optical elements, e.g. light-guiding paths
• G02B 1/00 - Optical elements characterised by the material of which they are made; Optical coatings for optical elements
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

An exemplary system and method can be provided, e.g., for detecting a molecular size and charge. The exemplary system can comprise a cavity, nanopores separated by the cavity, and electrolyte reservoirs. Each of the reservoirs can be provided on a side of a respective nanopore, and within the cavity. A plurality of such systems can be integrated in a surface of a complementary metal-oxide-semiconductor (CMOS) integrated circuit, which can comprise transimpedance amplifiers configured to measure a conductance through the nanopores. Further an exemplary device can be provided for protein sequencing, and can comprise a first compartment with a first electrode, a second compartment with a second electrode, and a channel between the first and second compartments. Each of the compartments can be fluidly coupled to the channel using a nanopore. A detector can also be provided which is configured to record at least one parameter in the channel by applying a voltage bias across the first and second electrodes so that charged molecules pass through the nanopore fluidly coupled to the first and second compartments.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

Abstract

In one or more implementations, systems, methods and computer implemented processes are provided that are directed to a method of treating a subject with a lung tumor, the method comprising: obtaining computed tomography (CT) image slices of the subject, wherein the CT image slices comprise images of the lung tumor. In a further implementation, the systems, methods and computer implemented processes are directed to identifying a first CT image slice where the lung tumor has a largest diameter among the CT image slices; and determining intensity-skewness of the lung tumor on the first CT image slice. In a further implementation, the systems, methods and computer implemented processes are directed to treating the subject with surgery, chemotherapy and/or radiotherapy, if the intensity-skewness is no greater than -1.5.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/136 - Segmentation; Edge detection involving thresholding
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Abstract

The present disclosure provides, inter alia, specially designed DNA adaptors and methods of preparing the same. Methods and kits for carrying out and detecting marker-free precision genome editing and genetic variation using such adaptors are also provided.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C40B 60/14 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
• B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

The present invention provides a compound having the structure: The present invention provides a compound having the structure: The present invention provides a compound having the structure: wherein X1 is H or alkyl; Y1 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -cycloalkyl, -aryl, heteroaryl, -alkyl-Y3 or -alkyl-C(O)Y4, and Y2 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -cycloalkyl, -aryl, heteroaryl, -alkyl-Y3 or -alkyl-C(O)Y4, wherein each Y3 is, independently, —OH, -O(alkyl), —NH2, -NH(alkyl) or halogen, and each Y4 is, independently, —OH, -O(alkyl), —NH2, -NH(alkyl) or -N(alkyl)2; Z1 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -aryl, heteroaryl, -alkyl-Z3 or -alkyl-C(O)Z4, and Z2 is H, -alkyl, -alkenyl, -alkynyl, alkylaryl, -aryl, heteroaryl, -alkyl-Z3 or -alkyl-C(O)Z4, wherein each Z3 is, independently, —OH, -O(alkyl), —NH2, -NH(alkyl) or halogen, and each Z4 is, independently, —OH, -O(alkyl), —NH2, -NH(alkyl) or -N(alkyl)2; R1, R2, R3 and R4 are each, independently, —H, —F, —Cl, —Br, —I, —NO2, —CN, —CF3, —CF2H, —OCF3, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), —OH, —OAc, -O-(alkyl), -O-(alkenyl), -O-(alkynyl), -O-(aryl), -O-(heteroaryl), —SH, -S-(alkyl), -S-(alkenyl), -S-(alkynyl), -S-(aryl), -S-(heteroaryl), —NH2, -NH-(alkyl), -NH-(alkenyl), -NH-(alkynyl), -NH-(aryl), -NH-(heteroaryl), -C(O)R5, -S(O)R5, -SO2R5, -NHSO2R5, -OC(O)R5, -SC(O)R5, -NHC(O)R6 or -NHC(S)R6, wherein each R5 is, independently, -(alkyl), -(aryl), -(heteroaryl), —OH, -O(alkyl), —NH2, -NH(alkyl) or -N (alkyl) 2, and wherein each R6 is, independently, -(alkyl), -(aryl), -O-(alkyl), -S-(alkyl), -S-(aryl), —NH2, -NH(alkyl) or -N (alkyl) 2, wherein the compound is other than any of ibogaine, ibogamine, N-methyl-ibogaine, N-methyl-noribogaine, N-ethyl-noribogaine, N-methyl-ibogamine or 10-ethoxy-ibogamine, or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, substance use disorders, opioid use disorders, and opioid withdrawal symptoms.

IPC Classes  ?

• C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides

Abstract

The present invention provides a compound having the structure: The present invention provides a compound having the structure: wherein X is CR6 or N; R1, R2, R3, R4, and R6 are each independently —H, —F, —Cl, —Br, —I, —NO2, —CN, —CF3, —CF2H, —OCF3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), —OH, —OAc, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —C(O)R7, —S(O)R7, —SO2R7, —NHSO2R7, —OC(O)R7, —SC(O)R7, —NHC(O)R8 or —NHC(S) R8, wherein R7 is, H, -(alkyl), —OH, —O(alkyl), —NH2, —NH(alkyl) or —N(alkyl)2, and wherein R8 is, -(alkyl), —O-(alkyl), —NH2, —NH(alkyl) or —N(alkyl)2; Y is O, S, N, NH, or a bond; Z is O, S, N, NH, (CH2)o, or a bond; R5 is H, OH, halogen, alkyl, or R5 is (CH2)p and is bound to Y when Y is N to form a ring together with Z; o and p are independently 0, 1, 2, or 3; m and n are independently 0, 1, 2, 3, or 4; A, C, and D are each independently N or CR9; R9 is H, halogen, —OH, alkyl, cycloalkyl, cycloalkylalkyl, —O-(alkyl), —S-(alkyl), —NH2, —NH(alkyl), —NH(alkyl)2, —CO2H, —CO(O-alkyl); B and E are N, CR9, or CFG wherein at least one of B or E is CFG; F is absent or present, and when present is The present invention provides a compound having the structure: wherein X is CR6 or N; R1, R2, R3, R4, and R6 are each independently —H, —F, —Cl, —Br, —I, —NO2, —CN, —CF3, —CF2H, —OCF3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), —OH, —OAc, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —NH-(aryl), —NH-(heteroaryl), —C(O)R7, —S(O)R7, —SO2R7, —NHSO2R7, —OC(O)R7, —SC(O)R7, —NHC(O)R8 or —NHC(S) R8, wherein R7 is, H, -(alkyl), —OH, —O(alkyl), —NH2, —NH(alkyl) or —N(alkyl)2, and wherein R8 is, -(alkyl), —O-(alkyl), —NH2, —NH(alkyl) or —N(alkyl)2; Y is O, S, N, NH, or a bond; Z is O, S, N, NH, (CH2)o, or a bond; R5 is H, OH, halogen, alkyl, or R5 is (CH2)p and is bound to Y when Y is N to form a ring together with Z; o and p are independently 0, 1, 2, or 3; m and n are independently 0, 1, 2, 3, or 4; A, C, and D are each independently N or CR9; R9 is H, halogen, —OH, alkyl, cycloalkyl, cycloalkylalkyl, —O-(alkyl), —S-(alkyl), —NH2, —NH(alkyl), —NH(alkyl)2, —CO2H, —CO(O-alkyl); B and E are N, CR9, or CFG wherein at least one of B or E is CFG; F is absent or present, and when present is G is H, substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, aryl, heteroaryl, alkyl, cycloalkyl, cycloalkylalkyl, CO2H, COOR10, OH, OR10, NH2, NHR10, NR10R11, SO2(alkyl), SO2(cycloalkyl), SO2(cycloalkylalkyl), CH2NHR10, CH2NR10R11, or CH2COOR10, wherein each R10 and R11 are each independently H, alkyl, cycloalkyl, —C(O)-alkyl, —C(O)-cycloalkyl, —C(O)OH, —C(O)—O-alkyl, —C(O)—O-cycloalkyl, —C(O)NH2, —C(O)NH(alkyl), —C(O)NH(cycloalkyl), —C(O)N(alkyl)2, —CH2NH(alkyl), —CH2COOH, —SO2CH3, —OH, —O(alkyl), —NH2, —NH(alkyl), —N(alkyl)2, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 487/10 - Spiro-condensed systems
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 27/02 - Ophthalmic agents

Abstract

Disclosed are methods, systems, and other implementations for processing and managing high volume complex data (such as captured neural signals data). The implementations include a method that includes receiving at a first network device, from a remote, second network device, a remote procedure call (RPC) message comprising a first data representation of neural signal data obtained by the second network device and servicing data specifying parameters to cause execution of a first servicing procedure executable on the first network device, performing the first servicing procedure to process the first data representation of the neural signal data to generate result data, and transmitting, by the first remote network device, another RPC message to a destination network device, the other RPC message including the result data.

IPC Classes  ?

• H04L 67/133 - Protocols for remote procedure calls [RPC]
• G06F 16/25 - Integrating or interfacing systems involving database management systems
• G06F 9/54 - Interprogram communication
• G06N 3/092 - Reinforcement learning
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

The method of enhancing anti-tumor immunity in a patient by targeting the CD58:CD2 axis uses an administered treatment to target and disrupt CMTM6 regulation of PD-L1 protein, thus enhancing the immune response and cancer immunotherapy in the patient. Targeting and disruption of CMTM6 regulation of the PD-L1 protein may be combined with additional prompting of a PD-1 blockage or adoptive cell transfer (ACT) in the patient. Targeting and disrupting CMTM6 regulation of PD-L1 protein may be initiated by administering an effective amount of antibodies to the patient, which are specific to disrupting CMTM6/PD-L1 protein interaction. Alternatively, to enhance the anti-tumor immunity in the patient, CD2 mediated signaling may be increased in order to stimulate an immune response. As another alternative to using antibodies or a CD58 mimetic, a pharmacological target to boost CD2/CD58 signaling in the patient may be identified and administered to enhance anti-tumor immunity.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

Abstract

An exemplar system, and computer-accessible medium for determining phenotypic (e.g., multi-parameter) information for a cell(s) can include, for example, generating spectral information of the cell(s) using a Raman spectroscopy procedure that is based on a vibrational probe(s), and determining the metabolic, protein biomarker, or signaling pathway information based on the spectral information. The Raman spectroscopy procedure can be a single-cell spontaneous Raman spectroscopy procedure. The single-cell Raman spectroscopy procedure can be performed using a whole-cell confocal micro-Raman spectrometer. The vibrational probe(s) can include a Deuterium-labeled branched-chain amino acid(s), or a deuterium-labeled palmitic acid(s), Raman active nanoparticles or other essential metabolites such as glucose and water.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 15/14 - Electro-optical investigation

Abstract

Immunosuppressive peptide fragments of MMP-13, pharmaceutical compositions comprising said peptides, and methods of inhibiting T cell proliferation.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The present disclosure provides compositions and methods for disrupting the interaction of a siglec protein and its binding partners, and thereby treating neurodegenerative disease.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

A microscope routes excitation light through a first set of optical components so the excitation light is projected into a sample and forms a sheet of excitation light at an oblique angle. The position of the sheet varies depending on an orientation of the scanning element. The first set of optical components routes detection light back to the scanning element, which routes the detection light into a second set of optical components. The second set of optical components forms an intermediate image plane that is imaged onto a detector. In some embodiments, a folding mirror is disposed between the first and second sets of optical components. In some embodiments, an optically transparent spacer covers the first objective and is configured to press against tissue being imaged. This spacer sets the working distance for the first objective to capture a particular range of depths within the tissue.

IPC Classes  ?

• G02B 21/00 - Microscopes

Abstract

The present disclosure relates to methods and compositions for preventing and/or treating liver fibrosis, liver cancer, and/or liver disease. In particular, the present disclosure relates methods and compositions which to decrease or inhibit microRNA found to be upregulated in liver fibrosis, liver cancer, and/or liver disease, or increase or activate microRNA found to be downregulated in liver fibrosis, liver cancer and/or liver disease. The present disclosure also relates to the use of engineered exosomes or extracellular vesicles in the methods and compositions for targeted delivery of the agents to the liver.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Disclosed here are compositions and methods for the detection of at least one virus viruses using a one-step assay. The viruses to be detected include at least SARS-CoV-2 and influenza viruses. In particular, the disclosure relates to a method of detection of the viruses using specific primers and probes designed to detect and if necessary differentiate between the viruses.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

Disclosed are methods, systems, and other implementations for processing, analyzing, and modelling psychotherapy data. The implementations include a method for analyzing psychotherapy data that includes obtaining transcript data representative of spoken dialog in one or more psychotherapy sessions conducted between a patient and a therapist, extracting speech segments from the transcript data related to one or more of the patient or the therapist, applying a trained machine learning topic model process to the extracted speech segments to determine weighted topic labels representative of semantic psychiatric content of the extracted speech segments, and processing the weighted topic labels to derive a psychiatric assessment for the patient.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnics; Testing reaction times
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G10L 17/02 - Preprocessing operations, e.g. segment selection; Pattern representation or modelling, e.g. based on linear discriminant analysis [LDA] or principal components; Feature selection or extraction
• G10L 17/14 - Use of phonemic categorisation or speech recognition prior to speaker recognition or verification
• G10L 17/22 - Interactive procedures; Man-machine interfaces
• G10L 25/66 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for extracting parameters related to health condition
• G10L 17/18 - Artificial neural networks; Connectionist approaches
• G10L 21/028 - Voice signal separating using properties of sound source
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons